CD274 and neoplasm: The PARP inhibitor talazoparib, in combination with palbociclib and nano-PROTACs for palbociclib, has been shown to increase the expression of PD-L1 in tumor cells and synergistically enhance the effect of immune checkpoint blockade in immunocompetent mouse colorectal cancer models [75,96].